3SBio: The Frequent Board Turnover Is Just the Tip of the Iceberg of a Larger Governance Issue
3SBio, based in China develops, manufactures, markets and sells biopharmaceuticals. The company owns market-leading biopharmaceuticals franchises...
367 Views
3SBio: Valuation Trap with Tell-Tale Signs of Corporate Governance Issues
3SBio is a leading pharmaceutical company in China. It has a dominant market share in two of its key products. Recently, the company's share price...
416 Views
Hong Kong Short Reporting - Insights from 12 July Data
We analyse the latest SFC data released last evening on short position reporting in Hong Kong for the week ended 12 July.Total short notional in...
529 Views
SinoMab (中国抗体): Pipeline Concentrated on Autoimmune Therapy
SinoMab, the first Hong Kong-headquartered biotech company coming to list on the SEHK, plans to raise USD100 to 200 million. In this insight, we...
896 Views
Hansoh Pharma IPO: Valuation Reasonable for the Trade-Offs
Hansoh Pharmaceutical (3692 HK) claims to be one of the few R&D driven Chinese pharmaceutical companies. It announced its IPO price range of...
830 Views